Louis Cantilena, Jr., M.D, Ph.D.
Studies associated with:
|Division||Study Number||Title||Investigator(s)||Release Date|
|DTMC||NIDA-CPU-0005||Double-blind, placebo-controlled, safety and pharmacology study with 75 mg dosage of GBR 12909 in cocaine experienced African American Volunteers.||Louis Cantilena, Jr., M.D, Ph.D.|
|DTMC||NIDA-CPU-0003||Phase I, Double-Blind, Placebo-Controlled Dose Escalating Assessment of Potential Interactions Between Intravenous Cocaine and RPR 102681||Louis Cantilena, Jr., M.D, Ph.D.|
|DTMC||NIDA-CPU-0002||Double-Blind, Placebo-Controlled, Dose Escalating, Safety and Pharmacology Study With Three Dosages of GBR 12909 in Cocaine Experienced Volunteers||Louis Cantilena, Jr., M.D, Ph.D.|